Literature DB >> 21951063

Cannabinoid CB(2) receptors modulate ERK-1/2 kinase signalling and NO release in microglial cells stimulated with bacterial lipopolysaccharide.

Stefania Merighi1, Stefania Gessi1, Katia Varani1, Carolina Simioni1, Debora Fazzi1, Prisco Mirandola1, Pier Andrea Borea1.   

Abstract

BACKGROUND AND
PURPOSE: Cannabinoid (CB) receptor agonists have potential utility as anti-inflammatory drugs in chronic immune inflammatory diseases. In the present study, we characterized the signal transduction pathways affected by CB(2) receptors in quiescent and lipopolysaccharide (LPS)-stimulated murine microglia. EXPERIMENTAL APPROACH: We examined the effects of the synthetic CB(2) receptor ligand, JWH-015, on phosphorylation of MAPKs and NO production. KEY
RESULTS: Stimulation of CB(2) receptors by JWH-015 activated JNK-1/2 and ERK-1/2 in quiescent murine microglial cells. Furthermore, CB(2) receptor activation increased p-ERK-1/2 at 15 min in LPS-stimulated microglia. Surprisingly, this was reduced after 30 min in the presence of both LPS and JWH-015. The NOS inhibitor L-NAME blocked the ability of JWH-015 to down-regulate the LPS-induced p-ERK increase, indicating that activation of CB(2) receptors reduced effects of LPS on ERK-1/2 phosphorylation through NO. JWH-015 increased LPS-induced NO release at 30 min, while at 4 h CB(2) receptor stimulation had an inhibitory effect. All the effects of JWH-015 were significantly blocked by the CB(2) receptor antagonist AM 630 and, as the inhibition of CB(2) receptor expression by siRNA abolished the effects of JWH-015, were shown to be mediated specifically by activation of CB(2) receptors. CONCLUSIONS AND IMPLICATIONS: Our results demonstrate that CB(2) receptor stimulation activated the MAPK pathway, but the presence of a second stimulus blocked MAPK signal transduction, inhibiting pro-inflammatory LPS-induced production of NO. Therefore, CB(2) receptor agonists may promote anti-inflammatory therapeutic responses in activated microglia.
© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21951063      PMCID: PMC3372829          DOI: 10.1111/j.1476-5381.2011.01673.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  56 in total

1.  Guide to Receptors and Channels (GRAC), 5th edition.

Authors:  Stephen P H Alexander; Alistair Mathie; John A Peters
Journal:  Br J Pharmacol       Date:  2011-11       Impact factor: 8.739

Review 2.  CB2: a cannabinoid receptor with an identity crisis.

Authors:  Brady K Atwood; Ken Mackie
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

Review 3.  Functionally selective cannabinoid receptor signalling: therapeutic implications and opportunities.

Authors:  Barbara Bosier; Giulio G Muccioli; Emmanuel Hermans; Didier M Lambert
Journal:  Biochem Pharmacol       Date:  2010-03-03       Impact factor: 5.858

4.  Activation of cannabinoid CB2 receptor negatively regulates IL-12p40 production in murine macrophages: role of IL-10 and ERK1/2 kinase signaling.

Authors:  Fernando Correa; Leyre Mestre; Fabian Docagne; Carmen Guaza
Journal:  Br J Pharmacol       Date:  2005-06       Impact factor: 8.739

Review 5.  Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas.

Authors:  Nephi Stella
Journal:  Glia       Date:  2010-07       Impact factor: 7.452

6.  Attenuation of inducible nitric oxide synthase gene expression by delta 9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor- kappa B/Rel activation.

Authors:  Y J Jeon; K H Yang; J T Pulaski; N E Kaminski
Journal:  Mol Pharmacol       Date:  1996-08       Impact factor: 4.436

7.  Secreted beta-amyloid precursor protein activates microglia via JNK and p38-MAPK.

Authors:  Angela M Bodles; Steven W Barger
Journal:  Neurobiol Aging       Date:  2005-01       Impact factor: 4.673

8.  Inducible nitric oxide synthase activity of cloned murine microglial cells.

Authors:  S B Corradin; J Mauël; S D Donini; E Quattrocchi; P Ricciardi-Castagnoli
Journal:  Glia       Date:  1993-03       Impact factor: 7.452

9.  Caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and interleukin-8 expression in hypoxic human colon cancer cells.

Authors:  Stefania Merighi; Annalisa Benini; Prisco Mirandola; Stefania Gessi; Katia Varani; Carolina Simioni; Edward Leung; Stephen Maclennan; Pier Giovanni Baraldi; Pier Andrea Borea
Journal:  Mol Pharmacol       Date:  2007-05-08       Impact factor: 4.436

10.  A(2B) and A(3) adenosine receptors modulate vascular endothelial growth factor and interleukin-8 expression in human melanoma cells treated with etoposide and doxorubicin.

Authors:  Stefania Merighi; Carolina Simioni; Stefania Gessi; Katia Varani; Prisco Mirandola; Mojgan Aghazadeh Tabrizi; Pier Giovanni Baraldi; Pier Andrea Borea
Journal:  Neoplasia       Date:  2009-10       Impact factor: 5.715

View more
  17 in total

1.  Retracted: Cannabinoid CB(2) receptors modulate ERK-1/2 kinase signalling and NO release in microglial cells stimulated with bacterial lipopolysaccharide, by S Merighi, S Gessi, K Varani, C Simioni, D Fazzi, P Mirandola and P A Borea. British Journal of Pharmacology, volume 165(6): 1773-1788, published in March 2012; DOI 10.1111/j.1476-5381.2011.01673.x.

Authors: 
Journal:  Br J Pharmacol       Date:  2017-08       Impact factor: 8.739

Review 2.  Neuroprotection in Oxidative Stress-Related Neurodegenerative Diseases: Role of Endocannabinoid System Modulation.

Authors:  Janos Paloczi; Zoltan V Varga; George Hasko; Pal Pacher
Journal:  Antioxid Redox Signal       Date:  2017-07-18       Impact factor: 8.401

3.  Cannabinoid CB(2) receptor attenuates morphine-induced inflammatory responses in activated microglial cells.

Authors:  Stefania Merighi; Stefania Gessi; Katia Varani; Debora Fazzi; Prisco Mirandola; Pier Andrea Borea
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

Review 4.  CB2 Cannabinoid receptors as a therapeutic target-what does the future hold?

Authors:  Amey Dhopeshwarkar; Ken Mackie
Journal:  Mol Pharmacol       Date:  2014-08-08       Impact factor: 4.436

5.  In Vivo Imaging of Translocator Protein in Long-term Cannabis Users.

Authors:  Tania Da Silva; Sina Hafizi; Jeremy J Watts; Cynthia Shannon Weickert; Jeffrey H Meyer; Sylvain Houle; Pablo Rusjan; Romina Mizrahi
Journal:  JAMA Psychiatry       Date:  2019-12-01       Impact factor: 21.596

6.  Monoacylglycerol lipase inhibitor JZL184 prevents HIV-1 gp120-induced synapse loss by altering endocannabinoid signaling.

Authors:  Xinwen Zhang; Stanley A Thayer
Journal:  Neuropharmacology       Date:  2017-10-20       Impact factor: 5.250

7.  CB2 receptor activation inhibits the phagocytic function of microglia through activating ERK/AKT-Nurr1 signal pathways.

Authors:  Qi-Wen Han; Qian-Hang Shao; Xiao-Tong Wang; Kai-Li Ma; Nai-Hong Chen; Yu-He Yuan
Journal:  Acta Pharmacol Sin       Date:  2022-02-07       Impact factor: 7.169

Review 8.  Cannabinoids and GI Disorders: Endogenous and Exogenous.

Authors:  Zachary Wilmer Reichenbach; Ron Schey
Journal:  Curr Treat Options Gastroenterol       Date:  2016-12

Review 9.  Cannabinoid receptor 2: potential role in immunomodulation and neuroinflammation.

Authors:  Slava Rom; Yuri Persidsky
Journal:  J Neuroimmune Pharmacol       Date:  2013-03-08       Impact factor: 4.147

10.  The CB2-preferring agonist JWH015 also potently and efficaciously activates CB1 in autaptic hippocampal neurons.

Authors:  N Murataeva; K Mackie; A Straiker
Journal:  Pharmacol Res       Date:  2012-08-14       Impact factor: 7.658

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.